Healthy Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy of a Patented Whole Cell Algae Fermentate on Gut Health in Healthy Adults With Mild Gastrointestinal Issues
NCT number | NCT04735809 |
Other study ID # | BIO-1901 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 21, 2019 |
Est. completion date | June 20, 2020 |
Verified date | March 2019 |
Source | Kemin Foods LC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of the current study is to evaluate the effect of whole cell fermentate on gut health, including GI system function, such as supporting consistency and regularity of bowel habits, as well as changes in microbiota. The role of the GI system can also be extended to immune regulation because approximately 70% of the entire immune system in the body is located around the gut. Thus, the health and wellbeing of the gut can have a great impact on whole-body health. Therefore, this study will assess the effect on overall immune function.
Status | Completed |
Enrollment | 70 |
Est. completion date | June 20, 2020 |
Est. primary completion date | December 20, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Subject is a male or female, 21-60 years of age 2. Subject has a BMI of 18.5-34.9 kg/m2 3. Subject reports having mild GI issues 4. Subject is willing and able to comply with the collection and storage requirements of the stool samples 5. Subject has internet access via computer, phone or other device and is able to maintain internet access throughout the trial in order to complete online daily questionnaires 6. Subject is a non-user of all tobacco, smoking products and nicotine products 7. Subject is willing to maintain physical activity patterns, body weight, supplements/medications, sleep patterns, and habitual diet throughout the trial. 8. Subject has no health conditions that would prevent him from fulfilling the study requirements 9 Subject understands the study procedures and signs forms providing informed consent to participate in the study Exclusion Criteria: 1. Subject has an abnormal laboratory test result(s) of clinical importance at Visit 1 2. Subject has a clinically important GI condition that would potentially interfere with the evaluation of the study product 3. Subject has a history or presence of uncontrolled and/or clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including type 1 and type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including unstable depression and/or unstable anxiety disorders) or biliary disorders 4. Subject has a known allergy, intolerance, or sensitivity to any of the ingredients in the study products 5. Subject has extreme dietary habits (e.g., Atkins diet, very high protein, very high fiber) 6. Subject has uncontrolled hypertension 7. Subject has a recent (within 6 weeks of Visit 1) diarrhea (defined as =3 loose or liquid stools/d) 8. Subject has participated in colonoscopy or colonoscopy preparation within 3 months prior to Visit 1 9. Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer 10. Subject has a history of bariatric surgery for weight reducing purposes 11. Subject has had a weight gain or loss of =5% body weight within 6 months of Visit 1 12. Subject has experienced any major trauma or any other surgical event within three months of Visit 1 13. Subject has any signs or symptoms of an active infection (including diarrhea) of clinical relevance within 5 days of Visit 1 14. Subject has used antibiotics within 3 months of Visit 1 or throughout study period 15. Subject has used medications (over-the-counter or prescription) or dietary supplements known to influence GI function 16. Subject has used medications or supplements known to influence immune responses 17. Subject is a regular user (>3 times/week) of prescribed anti-inflammatory medications within 30 d of Visit 1 18. Subject is a regular user (i.e., >1 time per month) of allergy medications 19. Subject has used weight-loss medications 20. Subject is a female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period 21. Subject has a recent history of (within 12 months of screening; Visit 1; week -1) or strong potential for alcohol or substance abuse 22. Individual has a condition the Clinical Investigator believes would interfere with his ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk |
Country | Name | City | State |
---|---|---|---|
United States | Biofortis Innovation Services | Addison | Illinois |
Lead Sponsor | Collaborator |
---|---|
Kemin Foods LC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gastrointestinal symptom | Gastrointestinal Tolerability Questionnaire | After 4 weeks of each test period | |
Primary | Gastrointestinal ease and consistency | Bristol Stool Scale | After 4 weeks of each test period | |
Primary | Cold/Flu Symptoms | Wisconsin Upper Respiratory Symptom Survey | After 4 weeks of each test period | |
Secondary | Fecal Microbiome | Omnigene-GUT DNA Genotek | After 4 weeks of each test period | |
Secondary | Fecal biomarker 1 | Short Chain Fatty Acid | After 4 weeks of each test period | |
Secondary | Fecal biomarker 2 | Leaky Gut biomarker | After 4 weeks of each test period | |
Secondary | Stress Questionnaire | Perceived Stress Questionnaire | After 4 weeks of each test period | |
Secondary | Quality of Life Questionnaire | World Health Organization-Quality of Life Questionnaire | After 4 weeks of each test period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |